- Research article
- Open Access
- Open Peer Review
Non-hispanic whites have higher risk for pulmonary impairment from pulmonary tuberculosis
© Pasipanodya et al; licensee BioMed Central Ltd. 2012
- Received: 18 May 2011
- Accepted: 10 February 2012
- Published: 10 February 2012
Disparities in outcomes associated with race and ethnicity are well documented for many diseases and patient populations. Tuberculosis (TB) disproportionately affects economically disadvantaged, racial and ethnic minority populations. Pulmonary impairment after tuberculosis (PIAT) contributes heavily to the societal burden of TB. Individual impacts associated with PIAT may vary by race/ethnicity or socioeconomic status.
We analyzed the pulmonary function of 320 prospectively identified patients with pulmonary tuberculosis who had completed at least 20 weeks standard anti-TB regimes by directly observed therapy. We compared frequency and severity of spirometry-defined PIAT in groups stratified by demographics, pulmonary risk factors, and race/ethnicity, and examined clinical correlates to pulmonary function deficits.
Pulmonary impairment after tuberculosis was identified in 71% of non-Hispanic Whites, 58% of non-Hispanic Blacks, 49% of Asians and 32% of Hispanics (p < 0.001). Predictors for PIAT varied between race/ethnicity. PIAT was evenly distributed across all levels of socioeconomic status suggesting that PIAT and socioeconomic status are not related. PIAT and its severity were significantly associated with abnormal chest x-ray, p < 0.0001. There was no association between race/ethnicity and time to beginning TB treatment, p = 0.978.
Despite controlling for cigarette smoking, socioeconomic status and time to beginning TB treatment, non-Hispanic White race/ethnicity remained an independent predictor for disproportionately frequent and severe pulmonary impairment after tuberculosis relative to other race/ethnic groups. Since race/ethnicity was self reported and that race is not a biological construct: these findings must be interpreted with caution. However, because race/ethnicity is a proxy for several other unmeasured host, pathogen or environment factors that may contribute to disparate health outcomes, these results are meant to suggest hypotheses for further research.
- Force Vital Capacity
- Directly Observe Therapy
- Pulmonary Impairment
- LTBI Treatment
- Foreign Birth
Health outcome disparities associated with race and ethnicity are well documented for many diseases and patient populations. While there are a variety of explanations for these effects, they are not fully understood [1–3]. Socio-economic, biological, cultural, demographic, and other factors all contribute to an individual's health before, during and after illness [1, 2, 4]. While some contributors to health disparities are well defined the contribution of biological and gender differences, personal behaviors, value choices, and race/ethnicity on specific diseases and their clinical outcomes are not [1, 3].
It is well established that tuberculosis (TB) is disproportionately prevalent among economically disadvantaged and racial/ethnic minority populations [5–8]. The health impacts of TB associated with differences in race, ethnicity, and more primary health risks are incompletely known [5–12]. In a prior study, we measured the frequency and degree of pulmonary impairment in TB patients who were treated with standard regimes delivered by directly observed therapy (DOT) . Spirometry-defined pulmonary impairment after tuberculosis (PIAT) was found in a majority of the cohort, and was more common in US born and older patients [13, 14]. The study's sample size did not allow stratified analysis of PIAT prevalence and severity between race/ethnic and other patient groups. We expanded our sample to allow a comparison of PIAT frequency across self-identified race/ethnicity groups and by socioeconomic status.
Patients and setting
This was a prospective cohort study of all patients 16 years of age and older receiving treatment for culture-confirmed pulmonary tuberculosis at Tarrant County Public Health (TCPH) from July 2005 to December 2009. The population includes all persons with culture-confirmed pulmonary tuberculosis in Tarrant County, some of whom also had concurrent extra-pulmonary tuberculosis. Texas requires all diagnosed TB cases be reported to the local public health authorities . TCPH is the health authority for an urban county with a 2010 population of 1,789,900 . TCPH provides treatment for all persons with TB within this jurisdiction, using universal DOT delivered to the patient's preferred location [15, 16]. All patients were treated with standard 4 drug American Thoracic Society (ATS) and Centers for Diseases and Prevention Control (CDC) recommended anti-TB regimens . Patients who had completed at least 20 weeks of this treatment were asked to participate in this study of their pulmonary function. The Institutional Review Board of the University of North Texas Health Science Center at Fort Worth approved the study; IRB project #24-109. All subjects gave written informed consent.
Pulmonary function testing
Pulmonary function tests (PFTs) by spirometry were performed on consenting patients. Spirometry was conducted according to ATS guidelines for maneuver, techniques and quality control using the Spirotouch device (Spirotouch Spirometry System 086578; Spacelabs Burdick; Deerfield, WI) [18, 19]. Patients with a history of bronchodilator use received nebulized albuterol 15 min before the test. Consistent results were considered variation of 5% or less between measurements on three separate tests. The best of three consistent results was used to grade pulmonary function.
Impairment was defined and graded using American Medical Association (AMA) guides for evaluation of permanent impairments . Forced Expiratory Volume in 1 min (FEV1) > = 80%, Forced Vital Capacity (FVC) > = 80% and FEV1/FVC > 70% of predicted were considered normal. Other results defined pulmonary impairment. Impairment was categorized as none, mild (if FEV1 or FVC was > 60% but < 80%), moderate (if FEV1 or FVC was 41% to 59%) or severe (if FEV1 or FVC was < 40%) using an interpretive algorithm from the AMA [18–20].
Trained research personnel obtained demographic data from patients at the time of enrolment using a standardized instrument. Data were double entered into a Microsoft Office 2003 ACCESS database (Microsoft Corporation, Redmond, WA. 98052). Subjects self-identified their race/ethnicity, and were given an option to identify themselves as Hispanic in accordance with US federal definitions . Because of their small numbers we combined self-identified Pacific Islanders, Native American Indians, and Arabs into one group.
Socioeconomic status was assessed according to established methods [22, 23] and included (1) highest level of education attained, (2) employment status at diagnosis, (3) self-identified occupation, and (4) estimate of household income. Education was categorized into quartiles of years < 12, 12, 12 to 15 and > 16 years. Similarly, area-median household income, derived from census-tract ZIP codes of the patient's home address, was divided into quartiles of < $27,250, $27,251 to $37 180, $37,180 to 52,777 and > $52,778; ranges comparable to published data from US TB patients [5, 24]. Homeless person who did not report income were treated as missing data. We scored patients' occupations using standard methods and correlated them to levels of education [22, 23, 25]. Occupational status was ranked according to prestige [22, 23, 25]. Education was then used as a proxy for socioeconomic status .
Time to beginning TB treatment, defined as the time from self-reported onset of symptoms to beginning tuberculosis therapy, was measured to give insight into patient-related factors associated with accessing healthcare . Ever smokers were patients who gave a history of current or past cigarettes smoking. Lifetime volume of cigarette exposure was estimated using pack-years. Exposure to solid fuel smoke (biomass exposure) and duration of biomass exposure was compared between groups.
Rubric to standardize chest radiographic findings
Cumulative diameter less than 2 cm
Cumulative diameter 2 to 4 cm
Cumulative diameter greater than 4 cm
Extent and pattern of infiltrating lesions
Occupy less than 25% of thoracic cavity
Occupy 25 to 49% of thoracic cavity
Occupy more than 50% of thoracic cavity
Parsimonious multivariate logistic regression models were constructed and analyzed for the full sample and separately for US-born, foreign-born persons and each racial/ethnic group. Both age and smoking have been shown to independently exacerbate pulmonary function decline so were included in all multivariate models [27–29]. The median age at which impairment and moderate/severe impairment occurred among the racial/ethnic groups were compared using Kaplan-Meir methods. Comparison between groups was performed using Chi-Square or Fisher's exact tests and/or analysis of variance (ANOVA) plus the Kruskal-Wallis tests when appropriate. Analysis was performed using SPSS version 12 for Windows (SPSS Inc; Chicago, IL) and GraphPad Prism version 5 (GraphPad Software; La Jolla, CA).
Demographic and clinical characteristics of 317 patients with pulmonary tuberculosis (TB) included in the analysis
n = 69
n = 85
n = 82
n = 81
Age (mean[SD]) years
Smoking volume(mean[SD]) pack-years
Exposed n (%)
Biomass Smoke Exposure duration
(mean [SD]) years
FVC (% predicted [SD])
FEV1 (% predicted[SD])
FEV1/FVC (% [SD])
Disease site and pattern
PTB and EPTB
Pattern of Impairment
Access (median [IQR]) Days to Begin TB Treatment
The median "time to beginning TB treatment" for non-impaired persons was 62 days (interquartile range [IQR] was 12-110); 93 days for mildly impaired persons (IQR 61-110), 138 days for moderately impaired subjects (IQR 32-271), and 37 days for severely impaired subjects (IQR 12-60). There was no significant association between race/ethnicity and time to beginning TB treatment, (p = 0.978) (Table 2). Similarly, no association between time to beginning treatment and PIAT was observed (p = 0.058) (data not shown).
Unadjusted odds ratio for some pulmonary impairment
OR (95% C.I)
5.18 (2.58, 10.42)
2.88 (1.53, 5.43)
2.02 (1.07, 3.81)
Days to Begin TB treatment
1.00 (1.00, 1.01)
Demographic and clinical characteristics
1.36 (0.84, 2.21)
2.30 (1.46, 3.61)
1.00 (0.64, 1.56)
Biomass Smoke Exposure
1.33 (0.77, 2.28)
No Biomass Smoke Exposure (reference)*
Smoking Volume (pack-year)
1.01 (1.00, 1.03)
1.02 (1.01, 1.03)
0.97 (0.93, 1.01)
Some Education (< 12 years)(reference)*
High School Graduate (12 years)
1.46 (0.86, 2.49)
Some College (13 - 15 years)
1.33 (0.67, 2.64)
College Graduate (16 or more year)
1.33 (0.64, 2.78)
1 (most prestigious)
1.17 (0.52, 2.67)
1.68 (0.90, 3.14)
4 (least prestigious)
1.41 (0.78, 2.56)
Area-median household income
< US$27 270 (reference)
US$27 271 - 37 180
0.82 (0.46, 1.46)
US$37 181 - 52 777
0.76 (0.40, 1.44)
1.55 (0.82, 2.92)
Predictors for pulmonary impairment in all 69 Whites, 85 Blacks, 82 Asians and 81 Hispanics with pulmonary tuberculosis
1.06 (1.01, 1.11)*
1.04 (1.00, 1.08)*
0.98 (0.95, 1.01)
1.02 (0.99, 1.05)
27.89 (1.02, 766.08)*
0.98 (0.31, 3.06)
0.28 (0.03, 3.08)
1.07 (0.27, 4.17)
Ever Smokers ‡
2.68 (0.48, 14.98)
1.09 (0.38, 3.11)
3.0 (1.15, 7.85)*
1.02 (0.39, 2.64)
Cox & Snell R-Square
Predictors for pulmonary impairment in 144 US- born patients with pulmonary tuberculosis
1.05 (1.02, 1.08)
1.77 (0.73, 4.29)
Non-Hispanic Whites †
4.94 (1.13, 21.63)
Non-Hispanic Blacks †
3.51 (0.81, 15.12)
In the U.S., racial/ethnic minorities and foreign-born persons face disparate risks for TB infection and higher levels of poor TB disease outcomes, including mortality [5–9]. We analyzed the relationship between race/ethnicity and PIAT in a cohort with culture-confirmed pulmonary tuberculosis that had completed a minimum of 20 weeks of therapy. We found that self-identified non-Hispanic White TB patients had disproportionately more frequent and severe pulmonary impairment relative to other race/ethnicities (72% vs. 48%), odds ratio (OR) of 3.15. These differences persist despite control for the effects of age, body mass index, smoking, access to medical treatment, foreign birth and socio-economic status. Among the potential explanatory variables analyzed, only age and race/ethnicity were significant predictors for impairment in US born persons. These data demonstrate a previously unrecognized disparate negative health impact to specific populations of TB patients.
Current U.S. policy does not consider older adults high-priority candidates for testing and treatment of LTBI unless they have specific risks for developing TB disease [17, 32]. These recommendations are based on the potential for adverse drug events associated with LTBI treatment. Predictors for PIAT varied between race/ethnic groups and by country of birth. We found the likelihood for PIAT to increases by an average 5% for each additional increase in age for US-born patients (Table 5; Figure 6). NHANES data showed that poorer lung function is also associated with poor clinical outcomes including premature death [30, 33]. This together with our findings suggests that moderate to severe PIAT may also be associated with earlier mortality. Future versions of LTBI treatment guidelines should consider reduction of tuberculosis burden from preventing PIAT as an additional treatment benefit.
Cigarette smoking, an established cause of pulmonary impairment, was significantly more prevalent among non-Hispanic Whites compared to other racial/ethnic groups. The proportion of non-Hispanic Whites impaired among never-smokers was 70% compared to 78% among ever-smokers. PIAT was more frequently encountered among non-Hispanic Whites compared to other racial/ethnic groups (p < 0.001), and when encountered was more likely to be severe (p = 0.001) (Figure 2) even after controlling for age and smoking (Figure 3, Tables 4). While there were more non-Hispanic Whites who smoked our data shows this difference is not sufficient to explain the more severe impairment found in non-Hispanic Whites.
Previous studies have investigated pulmonary sequelae of TB from a number of perspectives, but these are not readily generalized to US populations [31, 34–37]. Poh et al evaluated patients hospitalized for treatment with non-rifampin chemotherapy regimens and identified older age, disease severity at presentation and heavy smoking as predictors for pulmonary impairment . A population-based study from Latin America demonstrated that older age and repeated TB disease were associated with pulmonary impairment . Two South African studies of patients receiving inpatient treatment [34, 37] similarly demonstrated that repeated TB disease significantly increased risks for pulmonary impairment. Race/ethnicity was not explored in these studies [31,34,37. Despite management with best currently available therapy for tuberculosis we identified some PIAT in over half (52%) of patients and severe PIAT, in which less than 50% of personal lung function remains, in almost 1 in 10 patients (9%). Prevalence and severity of PIAT were not associated with diagnostic or treatment delay, suggesting that it occurs early among those with TB. Therefore, strategies to mitigate PIAT must primarily rely on prevention of active TB.
Our study failed to detect association between socioeconomic status and pulmonary impairment. This was an unexpected and novel finding. Poorer health outcomes are consistently associated with low socioeconomic status [1, 5, 23]. Despite Hispanics' lower socioeconomic status in our study cohort, and their higher TB incidence rates relative to other racial/ethnic groups in the US ; they enjoyed apparent protection against pulmonary impairment compared to other racial/ethnic groups. This finding supports what has been called the "healthy Hispanic Paradox," in which Hispanics experience disproportionately greater life expectancy relative to other racial/ethnic groups [38, 39]. Equity in health care access within the study area allowed by the public treatment of TB may explain health outcomes' independence from socioeconomic status.
There are several areas within our study vulnerable to ascertainment bias: such as the fact that race/ethnicity was self-reported, identification and grading of pulmonary impairment was biased towards an obstructive pattern and that the chest x-ray grading of impairment lacks consensus of standardization. Both race and ethnicity are contextual, mutually contradictory and usually assume socially defined constructs with no biologic basis such that even the definitions used by U.S. federal agencies change with every 10-year census [2, 40]. Even though mixed race/ethnicity is rare among self-identified non-Hispanic Whites, the US Hispanic population has a heterogeneous ethnic ancestry comprising of American Indian, European and African origins . In addition, 30% of self-identified US-born Blacks consider themselves of mixed race [41, 42]. As a result, the true effects of race/ethnicity on health outcomes may be difficult to clearly distinguish and are subject to confounding. Indeed, AMA grading is biased towards impairment that is obstructive in nature; hence patients with restrictive patterns might be under-represented in these estimates [18–20]. Given these limitations, it cannot be excluded that the findings reflect different phenotypic disease entities among different groups, of which some might be influenced by smoking and some not.
In conclusion, we found that pulmonary TB patients, who self-identified as non-Hispanic White, had more prevalent and more severe pulmonary impairment. The risk for pulmonary impairment remained after several factors such as smoking and socioeconomic status were controlled. Since race/ethnicity was self reported and race is not a biological construct, these findings must be interpreted with caution. However, because since race/ethnicity is a proxy for several other unmeasured host, pathogen or environment factors that may contribute to disparate health outcomes, these results are meant to suggest hypotheses for further research. Nevertheless, if these findings are confirmed among other populations in other locations, they suggest that the decision-making thresholds of risk of TB prevention strategies should be reconsidered to include the benefits of preventing PIAT.
This study could not have been completed without the TCPHD supplying study resources. We are indebted to the study participants whose participation made this study possible. We also are indebted to the Tuberculosis Epidemiologic Studies Consortium (TBESC) at the Centers for Disease Control and Prevention and to the Tuberculosis Trials Consortium (TBTC), which provided salary support for Drs. Pasipanodya, Munguia, Vecino, Weis, Miller, and Ms. Drewyer, although neither consortium directly funded this study, nor had any role in study design, data collection, data analysis, data interpretation, or writing of the report.
- Agency for Healthcare Research and Quality RM: National Healthcare Disparities Report; 2006. 2010, [http://www.ahrq.gov/qual/nhdr06/nhdr06.htm]Google Scholar
- Sankar P, Cho MK, Condit CM, Hunt LM, Koenig B, Marshall P, et al: Genetic research and health disparities. JAMA. 2004, 291: 2985-2989. 10.1001/jama.291.24.2985.View ArticlePubMedPubMed CentralGoogle Scholar
- U.S.Department of Health and Human Services, Washington D: Healthy people 2010. understanding and improving health and objectives for improving health. 2010, U.S. Government Printing Office, 2Google Scholar
- Settle K, Posner MR, Schumaker LM, Tan M, Suntharalingam M, Goloubeva O, et al: Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila). 2009, 2: 776-781. 10.1158/1940-6207.CAPR-09-0149.View ArticleGoogle Scholar
- Cantwell MF, McKenna MT, McCray E, Onorato IM: Tuberculosis and race/ethnicity in the United States: impact of socioeconomic status. Am J Respir Crit Care Med. 1998, 157: 1016-1020.View ArticlePubMedGoogle Scholar
- Schneider E: Tuberculosis among American Indians and Alaska Natives in the United States, 1993-2002. Am J Public Health. 2005, 95: 873-880. 10.2105/AJPH.2004.052456.View ArticlePubMedPubMed CentralGoogle Scholar
- Schneider E, Moore M, Castro KG: Epidemiology of tuberculosis in the United States. Clin Chest Med. 2005, 26: 183-95, v. 10.1016/j.ccm.2005.02.007.View ArticlePubMedGoogle Scholar
- Serpa JA, Teeter LD, Musser JM, Graviss EA: Tuberculosis disparity between US-born blacks and whites, Houston, Texas, USA. Emerg Infect Dis. 2009, 15: 899-904. 10.3201/eid1506.081617.View ArticlePubMedPubMed CentralGoogle Scholar
- Hinman AR: Disease prevention program for racial and ethnic minorities. Ann Epidemiol. 1993, 3: 185-192. 10.1016/1047-2797(93)90135-Q.View ArticlePubMedGoogle Scholar
- Pasipanodya JG, Miller TL, Vecino M, Munguia G, Bae S, Drewyer G, Weis SE: Using the St. George respiratory questionnaire to ascertain health quality in persons with treated pulmonary tuberculosis. Chest. 2007, 132 (5): 1591-1598. 10.1378/chest.07-0755.View ArticlePubMedGoogle Scholar
- Miller TL, McNabb SJ, Hilsenrath P, Pasipanodya J, Weis SE: Personal and societal health quality lost to tuberculosis. PLoS One. 2009, 4: e5080-10.1371/journal.pone.0005080.View ArticlePubMedPubMed CentralGoogle Scholar
- Miller TL, McNabb SJ, Hilsenrath P, Pasipanodya J, Drewyer G, Weis SE: The societal cost of tuberculosis: Tarrant County, Texas, 2002. Ann Epidemiol. 2010, 20: 1-7. 10.1016/j.annepidem.2009.09.004.View ArticlePubMedGoogle Scholar
- Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, Bae S, et al: Pulmonary impairment after tuberculosis. Chest. 2007, 131: 1817-1824. 10.1378/chest.06-2949.View ArticlePubMedGoogle Scholar
- Pasipanodya JG, McNabb SJ, Hilsenrath P, Bae S, Lykens K, Vecino E, et al: Pulmonary impairment after tuberculosis and its contribution to TB burden. BMC Publ Health. 2010, 10: 259-10.1186/1471-2458-10-259.View ArticleGoogle Scholar
- Tarrant County Public Health Department., Division of Tuberculosis Elimination. Tarrant County Public Health, Client Services: 2010Google Scholar
- Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, et al: The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994, 330: 1179-1184. 10.1056/NEJM199404283301702.View ArticlePubMedGoogle Scholar
- Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al: American thoracic society/centers for disease control and prevention/infectious diseases society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003, 167: 603-662.View ArticlePubMedGoogle Scholar
- Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al: Standardisation of spirometry. Eur Respir J. 2005, 26: 319-338. 10.1183/09031936.05.00034805.View ArticlePubMedGoogle Scholar
- Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al: General considerations for lung function testing. Eur Respir J. 2005, 26: 153-161. 10.1183/09031936.05.00034505.View ArticlePubMedGoogle Scholar
- Cocchiarella L, Andersson GBJ: The respiratory system. Guides to the Evaluation of Permanent Impairment. Edited by: Cocchiarella L, Andersson GBJ. 2000, Chicago: AMA Press, 5Google Scholar
- Office of Management and Budget: Revisions to the standards for the classification of federal data on race and ethnicity. 1997, 62: 58782-58790.Google Scholar
- Bureau of Labor Statistics: Occupational classification system manual. 1998Google Scholar
- Duncan O: A socioeconomic index for all occupations. Occupations and Social Status. Edited by: Reiss A Jr. 1961, New York: Free Press, 109-138.Google Scholar
- U.S.Census Bureau, State and County QuickFacts, State & County QuickFacts, US Census Bureau Population Estimates, Census of Population and Housing, Small Area Income and Poverty Estimates, State and County Housing Unit Estimates, County Business Patterns, Nonemployer Statistics, Economic Census, Survey of Business Owners, Building Permits: Consolidated Federal Funds Report. 2010, 5-26-2010Google Scholar
- Shavers VL: Measurement of socioeconomic status in health disparities research. J Natl Med Assoc. 2007, 99: 1013-1023.PubMedPubMed CentralGoogle Scholar
- Simon G: Radiology in epidemiological studies and some therapeutic trials. Br Med J (Clin Res Ed). 1966, 2: 491-494. 10.1136/bmj.2.5512.491.View ArticleGoogle Scholar
- Alexeeff SE, Litonjua AA, Sparrow D, Vokonas PS, Schwartz J: Statin use reduces decline in lung function: VA normative aging study. Am J Respir Crit Care Med. 2007, 176: 742-747. 10.1164/rccm.200705-656OC.View ArticlePubMedPubMed CentralGoogle Scholar
- Hassmiller KM: The association between smoking and tuberculosis. Salud Publica Mex. 2006, 48: (Suppl 1):S201-S216.View ArticleGoogle Scholar
- Kerstjens HA, Rijcken B, Schouten JP, Postma DS: Decline of FEV1 by age and smoking status: facts, figures, and fallacies. Thorax. 1997, 52: 820-827. 10.1136/thx.52.9.820.View ArticlePubMedPubMed CentralGoogle Scholar
- Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC: Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003, 58: 388-393. 10.1136/thorax.58.5.388.View ArticlePubMedPubMed CentralGoogle Scholar
- Menezes AM, Hallal PC, Perez-Padilla R, Jardim JR, Muino A, Lopez MV, et al: Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur Respir J. 2007, 30: 1180-1185. 10.1183/09031936.00083507.View ArticlePubMedGoogle Scholar
- Blumberg HM, Leonard MK, Jasmer RM: Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA. 2005, 293: 2776-2784. 10.1001/jama.293.22.2776.View ArticlePubMedGoogle Scholar
- Neas LM, Schwartz J: Pulmonary function levels as predictors of mortality in a national sample of US adults. Am J Epidemiol. 1998, 147: 1011-1018.View ArticlePubMedGoogle Scholar
- Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax. Edited by: Eva Hnizdo TSGC. 2000, 55: 32-38. 10.1136/thorax.55.1.32.Google Scholar
- Long R, Maycher B, Dhar A, Manfreda J, Hershfield E, Anthonisen N: Pulmonary tuberculosis treated with directly observed therapy: serial changes in lung structure and function. Chest. 1998, 113: 933-943. 10.1378/chest.113.4.933.View ArticlePubMedGoogle Scholar
- Poh SC: Airway obstruction in patients with treated pulmonary tuberculosis. Singapore Med J. 1975, 16: 43-47.Google Scholar
- Willcox PA, Ferguson AD: Chronic obstructive airways disease following treated pulmonary tuberculosis. Respir Med. 1989, 83: 195-198. 10.1016/S0954-6111(89)80031-9.View ArticlePubMedGoogle Scholar
- Lin CC, Rogot E, Johnson NJ, Sorlie PD, Arias E: A further study of life expectancy by socioeconomic factors in the National Longitudinal Mortality Study. Ethn Dis. 2003, 13: 240-247.PubMedGoogle Scholar
- Arias E: United States life tables, 2004. Natl Vital Stat Rep. 2007, 56: 1-39.PubMedGoogle Scholar
- U.S.Census Bureau: Population Estimates, Race/ethnicity. 2010, Accessed from http://www.census.gov/popest/race.html Google Scholar
- Kosoy R, Nassir R, Tian C, White PA, Butler LM, Silva G, et al: Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum Mutat. 2009, 30: 69-78. 10.1002/humu.20822.View ArticlePubMedPubMed CentralGoogle Scholar
- stro-Bisol G, Maviglia R, Caglia A, Boschi I, Spedini G, Pascali V, et al: Estimating European admixture in African Americans by using microsatellites and a microsatellite haplotype (CD4/Alu). Hum Genet. 1999, 104: 149-157. 10.1007/s004390050928.View ArticleGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2458/12/119/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.